ABT-737

Catalog No.S1002

ABT-737 Chemical Structure

Molecular Weight(MW): 813.43

ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in cell-free assays, respectively; no inhibition observed against Mcl-1, Bcl-B or Bfl-1. Phase 2.

Size Price Stock Quantity  
In DMSO USD 384 In stock
USD 120 In stock
USD 200 In stock
USD 570 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 92 Publications

17 Customer Reviews

  • Cardiomyocytes transduced with or without Ad-Mst1 were treated with ABT-737 (0, 0.1, 1, 10 uM) for 12 hours. Representative immunoblots with antibodies to p62/SQSTM1, LC3 and GAPDH are shown.

    Nat Med 2013 19(11), 1478-88. ABT-737 purchased from Selleck.

    Release of mitochondrial cytochrome c and loss of mitochondrial membrane potential after exposure to ABT-737 (100nM) for 2 hours were assessed by immunohistochemistry and staining with TMRE (red, top panels) and anti-CD41/FITC (green, top panels). Bar represents 5 um. Note that control cells display spreading on glass slides, whereas ABT-737-treated cells do not.

    Blood 2011 17(26), 7145-54. ABT-737 purchased from Selleck.

  • Platelets were incubated in HBS with or without ABT-737 (100nM) for 2 hours before analysis by immunohistochemistry and confocal microscopy. Actin was stained using phalloidin/Alexa-488 (green), and tubulin was stained using anti-tubulin/phycoerythrin (red). Bar represents 5 uM.

    Blood 2011 17(26), 7145-54. ABT-737 purchased from Selleck.

    BCL-XL mediates human neutrophil survival. PMNs were preincubated with the BH3 mimetic ABT-737 (1–10 μM), then cultured in normoxia (gray bars) with or without GM-CSF (500 U/ml) or hypoxia (white bars)or 20 hours, and apoptosis was assessed by morphology (n = 4).

     

     

    J Clin Invest 2011 121, 1053-1063. ABT-737 purchased from Selleck.

  • Analysis of SW480 and SW620 cell sensitivity to the BH3-mimetic ABT-737. (a, b) Percentage of apoptosis in adherent or suspended SW480 (a) or SW620 (b) cells cultured in the presence (ABT-737) or absence (ctrl) of ABT-737 (1 uM).

    Cell Death Dis 2013 4, e801. ABT-737 purchased from Selleck.

    (B) The sensitivity (LD50) of CLL cells, assessed by annexin V staining after 48 h of treatment with ABT‐737, ABT‐263 or ABT‐199, was plotted against the pBcl‐2/Bcl‐2, Mcl‐1/Bcl‐2 and (pBcl‐2 + Mcl‐1)/Bcl‐2 ratios. Relative protein quantification was carried out with kodak carestream molecular imaging software and normalized to β‐actin. Spearman's correlation (r) and P values are shown. Data shown are representative of five independent experiments.

    Br J Pharmacol, 2016, 173(3):471-83. ABT-737 purchased from Selleck.

  • Bcl-XL/Bcl-2 inhibitor ABT-737 aggravates the proapoptotic effects of IL-1IFN-. INS-1E cells were transfected with single or smart Pool PUMA siRNAs and exposed to ABT-737 for 24 h. At this time point, cell death was measured by HO/PI, n  3. *, p  0.05; **, p  0.01.
     

     

     

    J Biol Chem 2010 285, 19919-19920. ABT-737 purchased from Selleck.

    Effect of ABT-737 on the cell viability of CCRF-CEM cells by treatments of AY4 (10 μg/ml), TRAIL (0.5 μg/ml), SAHA (1 μM),VPA (1 mM), or ABT-737 (10 μM) alone or in combination for 24 h prior to MTT assay.

     

     

    Apoptosis 2010 15, 1256-1269. ABT-737 purchased from Selleck.

  • Effects of ABT-737 and RES, applied alone and in combination, on the viability of MOLT-4 cells.

    Toxicol In Vitro, 2017, 42:38-46. ABT-737 purchased from Selleck.

    Upper panel ABT-737 inhibits TFK-1 and EGI-1 cell growth.Cells were exposed to ABT-737 at a concentration ranging from 1 to 50 lM. Following 72 h of incubation, growth inhibition was analyzed by crystal violet assay. Dose–effect plot of ABT-737 treatment is presented.

     

     

    Cancer Chemoth Pharm 2011 67, 557-567. ABT-737 purchased from Selleck.

  • Lower panel detection of PARP-1, cleaved caspase-9 and caspase-3, BCL-2 and MCL-1 in TFK-1 and EGI-1 cells after 72 h of ABT-737 treatment (1, 3, 10, 25,50 μM). Cell lysates were analyzed on Western blotting.

     

     

    Cancer Chemoth Pharm 2011 67, 557-567. ABT-737 purchased from Selleck.

    GSIXII synergized with ABT-737 to trigger apoptosis in breast cancer cells . Breast cancer cell lines were incubate d for 48 hours with 10μM GSIXII or DMSO (Ct) in combination or not with ABT-737, 1 μM. Then apoptosis was evaluated with Apo2.7 or Annexin-V staining and flow-cytometry analysis. Represented data are the means of positive cells ± SEM, from three independent experiments.(A) Suboptimal concentrations of GSIXII (5 μM) and 1 μM ABT-737 were used alone or in combination in MFU assay in MCF7 and BT549 cell lines. Results were obtained from three independent experiments and compared with mock-treated condition. (B) The 20 μM SAHM1 was used alone or in combination in MFU assay in MCF7 and BT549 cell lines. Results were obtained from three independent experiments and compared with the mock-treated condition.

    Biochem Biophys Res Commun 2013 408, 344-9. ABT-737 purchased from Selleck.

  • Apoptosis induced by BCL2-inhibitors in P-glycoprotein expressing cells. MDCKII wild type or MDR1 cells were exposed to different concentrations of ABT-737 (C) or ABT-263 (D) for 24 h before apoptosis was assessed by flow cytometry using externalization of phosphatidylserine.

    Biochem Biophys Res Commun 2012 408, 344-9. ABT-737 purchased from Selleck.

    3 μM ABT737 inhibited growth and viability of TF-1 cells and potentiated proapoptotic effects of 1 μM BIO after 72 hours treatment. TF-1 cells treated with both drugs exhibited more apoptotic cells compared to those treated with each single drug. ABT737 abrogated the protection from BIO-induced apoptosis provided by MS5 coculture.

     

     

    Exp Hematol 2010 38, 908-921. ABT-737 purchased from Selleck.

  • The combined use of ABT-737 and sorafenib changes the apoptotic effect. MC-3 cells were treated with the indicated compounds for 48 h. (A) Nuclear condensation and fragmentation were evaluated in DAPI-stained cells as described in the Materials and Methods (X400). (B) Live (green) and dead (red) cells were qualified using the Live/dead assay kit as described in the Materials and Methods (X200). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

    Arch Oral Biol, 2017, 73:1-6. ABT-737 purchased from Selleck.

    MEF wt and MEF Mcl-1 ko mice activating active caspase-3 using 1um ABT for 24h

     

     

    Dr. Arnim Weber of Medizinische Mikrobiologie und Hygiene Universitatsklinikum Freiburg. ABT-737 purchased from Selleck.

  • MDB-MA-231 cells were exposed to 30 um cisplatin in the absence or in thepresence of 100nm ABT-737.The cell were stained with Hoechst 33342,MitoTracker Red and Yo-pro-1.

     

     

    Dr. Zhang of Tianjin Medical University. ABT-737 purchased from Selleck.

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Description ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in cell-free assays, respectively; no inhibition observed against Mcl-1, Bcl-B or Bfl-1. Phase 2.
Features First-generation inhibitor of anti-apoptotic Bcl-2 proteins.
Targets
Bcl-2 [1]
(Cell-free assay)
Bcl-xL [1]
(Cell-free assay)
Bcl-w [1]
(Cell-free assay)
Bcl-B [1]
(Cell-free assay)
30.3 nM(EC50) 78.7 nM(EC50) 197.8 nM(EC50) 1.82 μM(EC50)
In vitro

ABT-737 shows low activity to Bcl-B and no effects to Mcl-1 and BFL-1. ABT-737 is sensitive to HL60, KG1 and NB4 cells with IC50 of 50 nM, 80 nM and 80 nM, respectively. ABT-737 induces apoptosis in HL60 cells, which due to decreased Bcl-2/Bax heterodimerization and has no effect on cell cycle distribution. ABT-737 also induces cytochrome c release from purified mitochondria and promotes conformational changes in Bax that are associated with apoptosis. [1] Resistant cells (Hela and MCF-7) can be sensitized to ABT-737 by approaches that down-regulate, destabilize, or inactivate Mcl-1. ABT-737 also causes Bax/BAK-dependent cytochrome c release only when Mcl-1 has been neutralized. [2] ABT-737 displaces Bim from Bcl2's BH3-binding pocket, allowing Bim to activate Bax, induce mitochondrial permeabilization, and rapidly commit the primary chronic lymphocytic leukemia (CLL) cells to death. [3] Knockdown of Mcl-1 with siRNA sensitizes two resistant SCLC cell lines H196 and DMS114 to ABT-737 by enhancing the induction of apoptosis. Likewise, up-regulation of Noxa sensitizes H196 cells to ABT-737. ABT-737 inhibits proliferation and induces apoptosis in many SCLC cell lines including NCI-H889, NCI-H1963, NCI-H1417, NCI-H146 and etc. Bcl-2 and Noxa may contribute mechanistically to the cellular response to ABT-737 in NCI-H146 cells. [4] A recent study shows that ABT-737 significantly induces apoptosis in HTLV-1 infected T-cell lines as well as in fresh ATLL cells. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
OCI-Ly1  M1HmZmNmdGxiVnnhZoltcXS7IFHzd4F6 Mn\YNlUxKG6PwrC= NETm[pU4OiCq MXXEUXNQ NWfSTVd2[2G3c3XkJFk4LSCub4PzJI9nKH[rYXLpcIl1gSCrbjDj[YxteyC2cnHud4Zm[3SnZDD3bZRpKEKFTE[gd4lTVkF? NVjLd4pYOjZ4NUeyPFg>
KG1a NYPheW5FS2WubDDWbYFjcWyrdImgRZN{[Xl? NH3SbFQxNTFyIN88US=> MnTzNlQhcA>? MYrEUXNQ M4rhNGlEPTB;Nz62PEDPxE1uIHTlZ5Jm[XOnczDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MUOyOlU2OjdzMh?=
Kasumi-1 MlzoR4VtdCCYaXHibYxqfHliQYPzZZk> M{D6S|AuOTBizszN M1nrbVI1KGh? MW\EUXNQ NUXlTnNpUUN3ME20Mlg4KM7:TTyg[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MVSyOlU2OjdzMh?=
KG1a NYrxTnJ6SXCxcITvd4l{KEG|c3H5 M3TQUFAuOTBizszN MXuyOEBp MnXzSG1UVw>? MYTpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NIni[mczPjV3MkexNi=>
Kasumi-1 Ml33RZBweHSxc3nzJGF{e2G7 NFqyXGUxNTFyIN88US=> Mny2NlQhcA>? NH;u[5NFVVOR MXrpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NFzwVGMzPjV3MkexNi=>
MC-3  Mn\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7RWXo2NzFyL{KwJO69VQ>? NUTZeJpJOjRiaB?= Ml7XSG1UVw>? MVrpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MYKyOlQ1PzZzNR?=
HN22  MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPUWYkzNjVxNz61M|IzNjVizszN M13WblI1KGh? M{LmbGROW09? NHfPfnlqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MYGyOlQ1PzZzNR?=
MC-3  NXXkSm0zSXCxcITvd4l{KEG|c3H5 MkizOU8yOC9{MDFOwG0> M{iwelI1KGh? MYXEUXNQ NEPTRphqdmS3Y3XzJINie3Cjc3WtcYVlcWG2ZXSgZZBweHSxc3nz NGn2[5kzPjR2N{[xOS=>
HN22  MoTXRZBweHSxc3nzJGF{e2G7 MViyMlUwPy53L{KyMlUh|ryP MWeyOEBp M4XnSmROW09? MmrKbY5lfWOnczDjZZNx[XOnLX3l[IlifGWmIHHwc5B1d3Orcx?= NHTYVlEzPjR2N{[xOS=>
MOLT-4 NFO1dVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlT5NVAuPTByMDDuUS=> NEnEVW84OiCq NXrlbnM3TE2VTx?= MYLJR|UxRTBwMUm4JO69VQ>? MX2yOlM6OjN|Mh?=
RS4;11 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk[0NVAuPTByMDDuUS=> M{TpOVczKGh? Ml\qSG1UVw>? NGqxdllKSzVyPUCuNFAzKM7:TR?= NEfXU4czPjN7MkOzNi=>
JURKAT MnXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonDNVAuPTByMDDuUS=> MXW3NkBp MoLZSG1UVw>? MVzJR|UxRTZ4IN88US=> NGfNeHgzPjN7MkOzNi=>
CEM R NXfvdWtFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrTNVAuPTByMDDuUS=> NGLIc3I4OiCq M4rsS2ROW09? NWj3SmpbUUN3ME21MlQh|ryP MlTMNlY{QTJ|M{K=
CEM S NE\IU2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofVNVAuPTByMDDuUS=> NX3JVlhYPzJiaB?= M4rh[WROW09? NUG2XohFUUN3ME2xNk4yKM7:TR?= M{S0WFI3Ozl{M{Oy
MOLT-4 MUXBdI9xfG:|aYOgRZN{[Xl? MkjGNVAuOTByMDDuUS=> MWmyOEBp M2LLfWROW09? MUjjZZV{\XNidHjlJINt\WG4YXflJI9nKEKlbD2yJIFv\CC2aHWg[I94dnKnZ4XsZZRqd25ib3[gRoNtNXiOIHHu[EBO[2xvMR?= M1rz[|I3Ozl{M{Oy
CEM S M324NWFxd3C2b4Ppd{BCe3OjeR?= NHv0PFEyOC1zMECwJI5O NFi2dXgzPCCq M2LHbGROW09? MkTuZ4F2e2W|IITo[UBkdGWjdnHn[UBw\iCEY3ytNkBidmRidHjlJIRwf26{ZXf1cIF1cW:wIH;mJGJkdC26TDDhcoQhVWOuLUG= NIXFWVIzPjN7MkOzNi=>
JURKAT MoLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWexNFAuOTByMDDuUS=> MYS0PEBp NWP5cVh5TE2VTx?= MnrRTWM2OD17NUZCtVkvOyCwTR?= NHf3TnQzPjF5MkK2PS=>
LOUCY MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml:yNVAxNTFyMECgcm0> NV7lbZJuPDhiaB?= MWrEUXNQ M3;X[2lEPTB;M{KuPOKyOTBwOTDuUS=> MmPVNlYyPzJ{Nkm=
WM-115 MkOxR4VtdCCYaXHibYxqfHliQYPzZZk> Mmi0NVAxyqCwTR?= NVLRO|NiPzJiaB?= MUjlcohidmOnczDjeZJkfW2rbj3pcoR2[2WmIHHueIkue3W{dnn2ZYzDqA>? NF\VV3ozPjFzNke3Oi=>
B16 M4DueWNmdGxiVnnhZoltcXS7IFHzd4F6 M{\VTlExOMLibl2= MVK3NkBp M{TKW4VvcGGwY3XzJIN2emO3bXnuMYlv\HWlZXSgZY51cS2|dYL2bZZidMLi MXeyOlEyPjd5Nh?=
HL-60  M1Hj[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2ToZVczKGh? MlTWTWM2OMLiPTCxNE44KG6P M1yz[lI3ODR3NkC5
MOLM-13  MoG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVO3NkBp NX;CfJZ3UUN3MNMgQUAzPy57IH7N MlzZNlYxPDV4MEm=
OCI-AML3 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1O1d|czKGh? NYniPG1QUUN3MNMgQUAyQTVyIH7N M{m0cFI3ODR3NkC5
BCWM.1 MmqzRZBweHSxc3nzJGF{e2G7 NH;OPVcxNTFwNjFOwG0> MnL4NlQhcA>? NXewdnRlcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NXXzVm92OjV6OUOyPVA>
MWCL-1 NYfHd2JLSXCxcITvd4l{KEG|c3H5 M3O4b|AuOS54IN88US=> Mn7PNlQhcA>? M3uwWYlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? M1vUWVI2QDl|Mkmw
MM.1s M3ywV2Fxd3C2b4Ppd{BCe3OjeR?= NHjsW48xNTFwNjFOwG0> MWOyOEBp MkfRbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? MkHNNlU5QTN{OUC=
HCT116 M1TqSmZ2dmO2aX;uJGF{e2G7 NXHkfJJUOy9zMDFOwG0> NHH1SmIyOsLiaNMg NYnXTWFZTE2VTx?= MVLpcoR2[2W|IHGg[I9{\S2mZYDlcoRmdnRiaX7jdoVie2ViaX6gUGM{Si2LSTDjc453\XK|aX;uJIFv\CCVUWPUUVEh\GWpcnHkZZRqd25? NVfzO3E1OjV5MUWwNlg>
HCT116 BAX BAK1 DKO MnTBSpVv[3Srb36gRZN{[Xl? NWrueodsOy9zMDFOwG0> MXmxNuKhcMLi MWHEUXNQ MYnpcoR2[2W|IHGg[I9{\S2mZYDlcoRmdnRiaX7jdoVie2ViaX6gUGM{Si2LSTDjc453\XK|aX;uJIFv\CCVUWPUUVEh\GWpcnHkZZRqd25? NGT0RYgzPTdzNUCyPC=>
HCT116 M3;mR2Z2dmO2aX;uJGF{e2G7 MUWxNEDPxE1? NIT3bZAyOsLiaNMg NGna[ohFVVOR NIDUdZhqdmO{ZXHz[ZMhT0[SLVzDN2IheHWwY4Th Mn3iNlU4OTVyMki=
HCT116 BAX BAK1 DKO NXPvWJFRTnWwY4Tpc44hSXO|YYm= MWexNEDPxE1? NYLR[GVPOTMEoHlCpC=> M16xXWROW09? M1PKWYlv[3KnYYPld{BITlBvTFOzRkBxfW6ldHG= NIjYOGUzPTdzNUCyPC=>
HCT116 MWjBeZRweGijZ4mgRZN{[Xl? NX\GSZlvOTBizszN NH7VcGUyOsLiaNMg MlLzSG1UVw>? MWPpcoR2[2W|IHGgZ49ueGyndHWgZZV1d3CqYXfpZ{Bz\XOyb37z[S=> NYTyfXY2OjV5MUWwNlg>
HCT116 BAX BAK1 DKO MYnBeZRweGijZ4mgRZN{[Xl? NGH4W20yOCEQvF2= NVnRT45bOTMEoHlCpC=> NES4b2RFVVOR NVSxcVZicW6mdXPld{BiKGOxbYDs[ZRmKGG3dH;wbIFocWNicnXzdI9ve2V? M165VVI2PzF3MEK4
U937 Mmn4RZBweHSxc3nzJGF{e2G7 Mo\vNE4yOjVvMjFOwG0> NW\2VI54OjRiaB?= NEPCcZNmdmijbnPld{BFUEFxWD2xNU1qdmS3Y3XkJIFxd3C2b4Ppdy=> MljaNlU4OTRyMkS=
U937  M1fZcWFxd3C2b4Ppd{BCe3OjeR?= M{XuXVAvPSEQvF2= MX[yOEBp NW[yXXl{\W6qYX7j[ZMh[2ynYY\h[4Uhd2ZiUFHSVEBidmRiY3HzdIF{\S1|IHHzJJdmdGxiYYOgUo95[SCuZY\lcC=> M372OVI2PzF2MEK0
HL-60 AAA-Bcl-2 NFL1TJBCeG:ydH;zbZMhSXO|YYm= M3HGNFAuPSEQvF2= NXPWWJl3PDhiaB?= NILGeWVKSzVyPUCuPFch|ryv78{MbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NHXzUGYzPTdzMUS2NC=>
HL-60 EEE-Bcl-2 M3ywWWFxd3C2b4Ppd{BCe3OjeR?= NWj2R25POC13IN88US=> MWW0PEBp M1PTS2lEPTB;NTFOwI3wxIxiaX7keYNmeyClZXzsJIFxd3C2b4Ppd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MWOyOVcyOTR4MB?=
U87 MlHJSpVv[3Srb36gRZN{[Xl? M1z0PFUxKM7:TR?= MmSyNlQhcA>? MVry[YR2[2W|IITo[UBuWk6DIHX4dJJme3Orb36gcIV3\Wy|IH;mJG1OWC1{LDDNUXAuOTRiYX7kJGJkdC1{ NH\RSVAzPTZ4N{[2Ny=>
K562 MWTD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MoLGNU0yOCEQvF2= NIDtOG01QCCq M3XufmROW09? M2fsUWlEPTB;Mk[uO{DPxE1? NW\leGFWOjV3OU[1OlE>
K562/Mcl -1-IRESBim Mo\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTlwMzFOwG0> M17IUVI2PTN3OUCw
K562/Bcl- 2-IRESBim MnPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\DV45jUUN3ME2wMlM2KM7:TR?= MYWyOVU{PTlyMB?=
Jurkat NIPkfHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXSWGRTUUN3ME2wMlY3KM7:TR?= MYGyOVU{PTlyMB?=
JurkatΔBak MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRjVyIN88US=> NYezcXlWOjV3M{W5NFA>
HL60/VCR MmjCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzGXm16UUN3ME6xNFAh|ryP MWCyOVU{PTlyMB?=
Kasumi-1 M{mzU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jBPGlEPTB;MD6wNUDPxE1? MljHNlU2OzV7MEC=
Kasumi-1/ABT MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTvTWM2OD1yLkWxJO69VQ>? MmfrNlU2OzV7MEC=
THP-1 NIDrPIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFK3fYxKSzVyPUGuNlch|ryP MX:yOVU{PTlyMB?=
U937 MkTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTVwMkmg{txO MmO2NlU2OzV7MEC=
C1498 M2G0NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7FTWM2OD14LkGzJO69VQ>? M2fuc|I2PTN3OUCw
RPMI 8226 MnLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPjWVlDUUN3ME2wMlI2KM7:TR?= NXixeoEzOjV3M{W5NFA>
MM.1S NHTWfJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\LUmlEPTB;MD60NEDPxE1? MUCyOVU{PTlyMB?=
NCI-H929 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HMOmlEPTB;MUWuNlEh|ryP NV;3V5dVOjV3M{W5NFA>
U266 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrBbY1KSzVyPUCuOlgh|ryP NWOzOot5OjV3M{W5NFA>
MCF-7 MVTD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NWPlUGw2PSEQvF2= MXO0PEBp MUjEUXNQ MVHlcohidmOnczD0bIUhe2Wwc3n0bZZqfHlidH:gc5IhemGmaXH0bY9v NGfrXVgzPTRyOUGyOC=>
MCF-7 NEXzOnpCeG:ydH;zbZMhSXO|YYm= MmS4OUDPxE1? MofMOE8zPC92ODDo Mn\BSG1UVw>? M1T6bolv[3KnYYPld{B1cGViY3zlZZZm\CCSQWLQ NVXDbYxiOjV2MEmxNlQ>
MCF-7 M1u0TGZ2dmO2aX;uJGF{e2G7 NYLmfnJ{PSEQvF2= NYr0[XM1OjRiaB?= NXvsS5V2TE2VTx?= NFnXemRmdmijbnPld{B1cGWuZY\lcEBw\iCPY3ytNUBmgHC{ZYPzbY9vyqB? NXrqdmpIOjV2MEmxNlQ>
MDA-MB 231  M1zFWWZ2dmO2aX;uJGF{e2G7 NYTRNogyPSEQvF2= M{DhU|I1KGh? Mnf1SG1UVw>? M3v2ToVvcGGwY3XzJJRp\WyndnXsJI9nKE2lbD2xJIV5eHKnc4Ppc47DqA>? MkHTNlU1ODlzMkS=
ZR-75-1  NH;qeoJHfW6ldHnvckBCe3OjeR?= MnTKOUDPxE1? NG\Ne2MzPCCq MWXEUXNQ Mkny[Y5p[W6lZYOgeIhmdGW4ZXygc4YhVWOuLUGg[ZhxemW|c3nvcuKh MYKyOVQxQTF{NB?=
A549 NXTDd2ZFS2WubDDWbYFjcWyrdImgRZN{[Xl? MWqwMVIxKM7:TR?= M2DzOVczKGh? MVnEUXNQ NYHNSYk2\GWlcnXhd4V{KHSqZTDj[YxtKHO3co\peoFtKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVzKGOxbXLpcoVlKHerdHigZZNxcXKrbh?= NULUNG9yOjV|OEi3OlI>
H1299 NFq5fm1E\WyuIG\pZYJqdGm2eTDBd5NigQ>? MUCwMVIxKM7:TR?= M3HrO|czKGh? NXHQPVNMTE2VTx?= Mnux[IVkemWjc3XzJJRp\SClZXzsJJN2en[rdnHsJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyJINwdWKrbnXkJJdqfGhiYYPwbZJqdg>? NE\SbFgzPTN6OEe2Ni=>
HO-8910 MXrD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M2TJeFAuOjBizszN NXrve4dFPzJiaB?= MV3EUXNQ M3:1NIRm[3KnYYPld{B1cGViY3XscEB{fXK4aY\hcEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldkBkd22kaX7l[EB4cXSqIHHzdIlzcW5? MlvzNlU{QDh5NkK=
HT-29 MorMR4VtdCCYaXHibYxqfHliQYPzZZk> NEPXRnIxNTJyIN88US=> MVe3NkBp MYrEUXNQ NWnId|Fw\GWlcnXhd4V{KHSqZTDj[YxtKHO3co\peoFtKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVzKGOxbXLpcoVlKHerdHigZZNxcXKrbh?= NUnIc3hKOjV|OEi3OlI>
HCT-116 Mn\qR4VtdCCYaXHibYxqfHliQYPzZZk> NUfGZlRLOC1{MDFOwG0> NV2zemc6PzJiaB?= NUDQTYZrTE2VTx?= NXrSVG81\GWlcnXhd4V{KHSqZTDj[YxtKHO3co\peoFtKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVzKGOxbXLpcoVlKHerdHigZZNxcXKrbh?= MWCyOVM5QDd4Mh?=
A549 NILYZ2dCeG:ydH;zbZMhSXO|YYm= NUDsSHVwOjBizszN NUPI[o1WPDhiaB?= NYDUTItyTE2VTx?= M2TMfIlv\HWlZYOgZZBweHSxc3nzJJNq\26rZnnjZY51dHliY3;tZolv\WRid3n0bEBie3Crcnnu NIfsfmwzPTN6OEe2Ni=>
H1299 MVPBdI9xfG:|aYOgRZN{[Xl? MXuyNEDPxE1? MUi0PEBp NIDMO4RFVVOR MV7pcoR2[2W|IHHwc5B1d3OrczDzbYdvcW[rY3HueIx6KGOxbXLpcoVlKHerdHigZZNxcXKrbh?= MXiyOVM5QDd4Mh?=
Sc-1 MX3D[YxtKF[rYXLpcIl1gSCDc4PhfS=> M1PIUlAvODByMT2xJO69VQ>? M{\MfVk3KGh? NFXCOWdl\WO{ZXHz[ZMhfGinIHPlcIwhfmmjYnnsbZR6KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NWK2UYNYOjV|N{O1NFg>
OcI-LY18 M2n5W2NmdGxiVnnhZoltcXS7IFHzd4F6 M32wN|AvODByMT2xJO69VQ>? MlPFPVYhcA>? MYDk[YNz\WG|ZYOgeIhmKGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MnfvNlU{PzN3MEi=
RL  MXrD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NF\OO2IxNjByMEGtNUDPxE1? MYm5OkBp NEDCd5Zl\WO{ZXHz[ZMhfGinIHPlcIwhfmmjYnnsbZR6KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MmTSNlU{PzN3MEi=
RKO NHnMTWdE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MoXWNE0yOCEQvF2= NWfGbGFPOjUkgJnoxsA> NIjQdpNFVVOR NFzuToRKSzVyPvMAjVI26oDLwsXN NIn5fVQzPTNyNEO4Ny=>
Caco-2 MYTD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MX[wMVExKM7:TR?= NV3zSHN2OjUkgJnoxsA> MkXUSG1UVw>? M4XIU2lEPTB;MUmuO-KBkcL3TR?= M3vTOVI2OzB2M{iz
DLD1 M4DlTmNmdGxiVnnhZoltcXS7IFHzd4F6 NVLKV5JSOC1zMDFOwG0> NELRN2UzPOLCiXlCpC=> MV\EUXNQ NX3VeIlHUUN3ME2xPE44QOLCidM1US=> NGnsbnQzPTNyNEO4Ny=>
LS411N NULZ[2wxS2WubDDWbYFjcWyrdImgRZN{[Xl? MViwMVExKM7:TR?= NIfKO4MzPOLCiXlCpC=> MXHEUXNQ MVjJR|UxRTFzLkS35qCKyrWP MV2yOVMxPDN6Mx?=
SW620 MkG0R4VtdCCYaXHibYxqfHliQYPzZZk> M3;mXFAuOTBizszN M{XSR|I16oDLaNMg MkLaSG1UVw>? MVHJR|UxRTF{LkK05qCKyrWP M3HWO|I2OzB2M{iz
HCT116 MWLD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MnvyNE0yOCEQvF2= NEjkU4YzPOLCiXlCpC=> M3q1e2ROW09? M1LYNmlEPTB;MkCuOFnjiIoEtV2= NX3lRYp4OjV|MESzPFM>
HaCaT M4rSO2NmdGxiVnnhZoltcXS7IFHzd4F6 NWH2SHFNOC5zL{GvNVAh|ryP MVKyOEBp MknlSG1UVw>? MW\k[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NF3H[ZgzPTJzMEe5OS=>
A5-RT3 MWHD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M1rFU|AvOS9zL{GwJO69VQ>? NH3oNnMzPCCq Mn3jSG1UVw>? Mmn6[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M2PIdFI2OjFyN{m1
HaCaT MXXGeY5kfGmxbjDBd5NigQ>? MkfDNVDjiIoQvF2= MW[yOE81QCCq NVHJOpJkTE2VTx?= NF\oc2FqdmS3Y3XzJG1OWCCjbnSgSG5CKG[{YXft[Y51[XSrb36= NHzMbGIzPTJzMEe5OS=>
A5-RT3 MlS1SpVv[3Srb36gRZN{[Xl? M3vGVFEx6oDLzszN Mnj6NlQwPDhiaB?= MWDEUXNQ M{fjOolv\HWlZYOgUW1RKGGwZDDEUmEh\nKjZ33lcpRifGmxbh?= MWSyOVIyODd7NR?=
A5-RT3 M1r6UWZ2dmO2aX;uJGF{e2G7 MVy1JO69VQ>? NV[wVGNxPiCq M1fVWmROW09? NWHJUphIcW6mdXPld{B1cGVicnXs[YF{\SCxZjDtbZRw[2ixbnTybYFtKHC{b4TlbY5{KGGwZDDy[YR2[2W|IHPsc45w\2WwaXOgd5Vzfmm4YXygbY4h[SClYYPwZZNmNWmwZHXw[Y5l\W62IH3hco5meg>? NEfyUIEzPTJzMEe5OS=>
U266 Mn;ySpVv[3Srb36gRZN{[Xl? MWW1NFAwPzVyIH7N MWWyOE81QCCq NYTMfIc6TE2VTx?= NIPkSI9ld3ewcnXneYxifGW|IFLpcUwheHKrbnPpdIFtdHlidHjlJGVNKGm|b3\vdo0> NX3SW5F{OjV{MEi4PFg>
RPMI8226 MULGeY5kfGmxbjDBd5NigQ>? NY\lSWcxPTByL{e1NEBvVQ>? Mo[2NlQwPDhiaB?= M4LmVmROW09? MXnkc5dvemWpdXzheIV{KEKrbTygdJJqdmOrcHHscJkhfGinIFXMJIl{d2[xcn2= NX;6OmptOjV{MEi4PFg>
MM.1S M1;wdWZ2dmO2aX;uJGF{e2G7 NI\Vbm42ODBxN{WwJI5O NIHiWYczPC92ODDo NGK5b3NFVVOR MmHJ[I94dnKnZ4XsZZRmeyCEaX2sJJBzcW6laYDhcIx6KHSqZTDFUEBqe2:ob4Lt M3nXZVI2OjB6OEi4
Clone A NUfNVnRYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLjNE4z6oDVNkCg{txO MmX0O|IhcA>? NGDKXlBFVVOR NUSwOmwzUUN3ME23MlUh|ryP NVvQRpQ5OjV{MEi4PFI>
CX-1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXRNE4z6oDVNkCg{txO MkntO|IhcA>? M4HUWWROW09? MnrZTWM2OD1zLkig{txO NF7jd|IzPTJyOEi4Ni=>
LS174T MmfCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXMNE4z6oDVNkCg{txO M1i5VlczKGh? NFPBOHhFVVOR NILVToVKSzVyPUG4MlMh|ryP MX2yOVIxQDh6Mh?=
HT29 NGfEUYFCeG:ydH;zbZMhSXO|YYm= NET3NYsyNzVxMUCg{txO M4rtclQ5KGh? NXfpOZNI[2G3c3XzJINmdGxiZHXheIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NHHvNmUzPTF7MkG4PC=>
SW480 NETKfZRCeG:ydH;zbZMhSXO|YYm= NHrKeIUyNzVxMUCg{txO NXL6OmlIPDhiaB?= M3XN[INifXOnczDj[YxtKGSnYYToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MnnnNlUyQTJzOEi=
Colo205 MlvBRZBweHSxc3nzJGF{e2G7 NUmzW4xtOS93L{GwJO69VQ>? MV60PEBp M3\hUoNifXOnczDj[YxtKGSnYYToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy M1PLZlI2OTl{MUi4
Caco2 MVfBdI9xfG:|aYOgRZN{[Xl? NEDJ[moyNzVxMUCg{txO MXm0PEBp NXG1OItl[2G3c3XzJINmdGxiZHXheIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MoLyNlUyQTJzOEi=
PCI-13 NWTMOlJoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nMblczKGh? NV25SFBzTE2VTx?= MX7HTVUxRTF3INMxJFEvQCEQvF2= MmjkNlUyOzl|OEe=
PCI-15B NFLuVYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\1NYc4OiCq M2f6SWROW09? M4S3fmdKPTB;MUGgxtEhPC53IN88US=> NH[xNmkzPTF|OUO4Oy=>
UM-SCC22B NIjETYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFW4b3Q4OiCq NEfzPHNFVVOR NE\jZo1IUTVyPUG5JOKyKDJwOTFOwG0> NX36PJJmOjVzM{mzPFc>
UM-SCC47 M{HyTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVi3NkBp NXjiV2tjTE2VTx?= M{fWVGdKPTB;MUmgxtEhOTJwMzFOwG0> NX3TbY4{OjVzM{mzPFc>
93-VU-147T M1fmVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWS3NkBp M2n0SWROW09? NEXJeVZIUTVyPUSuN{DDuSB|LkWg{txO Mm\JNlUyOzl|OEe=
UD-SCC2 Mo\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzy[YU4OiCq Mlf2SG1UVw>? MoXMS2k2OD1{ODFCtUAzNjlizszN MVGyOVE{QTN6Nx?=
UPCI:SCC90 M3js[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWn2UGpwPzJiaB?= MknISG1UVw>? MUnHTVUxRTZwNjFCtUAyNjVizszN MUmyOVE{QTN6Nx?=
RPMI-8226  NU\ORYxJS2WubDDWbYFjcWyrdImgRZN{[Xl? NW\KcG9MOTJ3L{K1NE82ODBibl2= MX[0PIjDqA>? MWLEUXNQ MVfk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NF3tfWszPTByOEKwNi=>
OPM-2  NHHzUo5E\WyuIG\pZYJqdGm2eTDBd5NigQ>? NXy5Z4h5OTJ3L{K1NE82ODBibl2= MlfuOFhpyqB? MlXWSG1UVw>? M1z1coRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NIPXSWIzPTByOEKwNi=>
RPMI-8226  MXvBdI9xfG:|aYOgRZN{[Xl? Mme4NVI2NzJ3MD:1NFAhdk1? M{nVNlQ5cMLi NVzwPWVVTE2VTx?= MXrpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MYCyOVAxQDJyMh?=
OPM-2  NUjtUWtYSXCxcITvd4l{KEG|c3H5 MUKxNlUwOjVyL{WwNEBvVQ>? NWXSXIRxPDiqwrC= M{TnbmROW09? MofQbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M1L5VlI2ODB6MkCy
COG-LL-319 MV7GeY5kfGmxbjDBd5NigQ>? M4jtTlExOCCwTR?= NELPb|UyNzNxNjDo NWnO[HdkTE2VTx?= M3zS[4lv\HWlZYOgZ4F{eGG|ZT3k[ZBmdmSnboSgUYNtNTFiY3zlZZZi\2V? MYeyOFk2OTR5Mh?=
RS4;11 Mke1SpVv[3Srb36gRZN{[Xl? MUKxNFAhdk1? MkiyNU8{NzZiaB?= MnfKSG1UVw>? NX7SWVZicW6mdXPld{Bk[XOyYYPlMYRmeGWwZHXueEBO[2xvMTDjcIVifmGpZR?= NGDjT3czPDl3MUS3Ni=>

... Click to View More Cell Line Experimental Data

In vivo In aggressive leukemia model, ABT-737 suppresses the leukemia burden by 53% at the 30 mg/kg, with significantly extended survival of mice. ABT-737 does not induce significantly abnormalities in blood cell counts or serum chemistries. [1] ABT-737 prolongs the survival of recipient mice transplanted with Bcl-2-transduced tumors. [2] ABT-737 shows great antitumor activity in an ATLL mouse model at a dose of 100 mg/kg. [5]

Protocol

Kinase Assay:

[1]

+ Expand

Fluorescence polarization assays:

Binding affinity of GST-Bcl-2 family proteins to the FITC-conjugated BH3 domain of Bim (FITC-Ahx-DMRPEIWIAQELRRIGDEFNAYYAR) is determined. Briefly, 100 nM of GST-Bcl-2 family fusion proteins are incubated with serial dilutions of ABT-737 in PBS for 2 min. Then, 20 nM of FITC-Bim BH3 peptide (FITC-Ahx-DMRPEIWIAQELRRIGDEFNAYYAR) is added. Fluorescence polarization is measured using an Analyst TM AD Assay Detection System after 10 min using the 96-well black plate. Then IC50 are determined.
Cell Research:

[4]

+ Expand
  • Cell lines: SCLC cell lines NCI-H889, NCI-H1963, NCI-H1417, NCI-H146, NCI-187, DMS79, NCI-1048, NCI-H82, NCI-H196, H69AR, and DMS114
  • Concentrations: 0.001-10 μM
  • Incubation Time: 48 hours
  • Method:

    SCLC cells are treated for 48 hours in 96-well tissue culture plates in a total volume of 100 μL tissue culture medium supplemented with 10% human serum. Viable cells are determined using the MTS assay.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Scid mice injected with Luc-expressing FD/ΔRaf-1:ER cells
  • Formulation: 1 g/mL stock solution of ABT-737 in DMSO is added to a mixture of 30% propylene glycol, 5% Tween 80, 65% D5W (5% dextrose in water) (pH 4−5; final concentration of DMSO ≤ 1%)
  • Dosages: 20 and 30 mg/kg
  • Administration: For intraperitoneal (i.p.) every day
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (122.93 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% Propylene glycol, 5% Tween 80, 65% D5W
For best results, use promptly after mixing.
30mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 813.43
Formula

C42H45ClN6O5S2

CAS No. 852808-04-9
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01440504 Completed Ovarian Cancer Centre Francois Baclesse|GRECAN April 2010 --

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What’s the recommended method about reconstitution of the compound for in vivo animal study?

  • Answer:

    For oral administration, we suggest the vehicle: 30% Propylene glycol, 5% Tween 80, 65% D5W, at up to 30mg/ml; For injection, ABT-737 can be dissolved in 2% DMSO/50% PEG 300/5% Tween 80/ddH2O at 2.5 mg/ml.

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Related Bcl-2 Products

Tags: buy ABT-737 | ABT-737 supplier | purchase ABT-737 | ABT-737 cost | ABT-737 manufacturer | order ABT-737 | ABT-737 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID